Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Clinical trial NCT02452554 · COMPLETED

Trial details

NCT number: NCT02452554
Sponsor: Children's Oncology Group
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Pleuropulmonary Blastoma Recurrent Malignant Peripheral Nerve Sheath Tumor Recurrent Neuroblastoma Recurrent Rhabdomyosarcoma Recurrent Synovial Sarcoma Wilms Tumor

Start date: 2015-10-12
Primary completion: 2017-06-30
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.